Naloxone: The Universal Antidote for Opioid Overdose
Release Date: October 30, 2015
Expiration Date: December 31, 2017
This educational activity is provided by Dannemiller
Supported by Kaleo.
Physicians, Nurse Practitioners, Pharmacists.
Upon completion of this activity, the participant should be able to:
- Identify patients at increased risk for opioid overdose and diagnose patients presenting with drug overdoses, including those patients with respiratory and central nervous system depression
- Evaluate recently developed treatments for opioid overdoses and their potential use by at-risk individuals and their families
- Educate patients and caretakers about how to administer naloxone, how to re-evaluate the patient as the naloxone wears off, and how to inform emergency personnel of known or suspected opioid overdose
Statement of Need
Every day, approximately 113 people die from a drug overdose in the United Sates. According to the Centers for Disease Control (CDC), 74% of the 22,810 deaths attributed to drug overdoses in 2011 involved opioid pain relievers or prescription painkillers.[i] Moreover, in 2007, prescription opioid abuse cost the United States 55.7 billion dollars, an amount that includes job loss and incarceration. Overdoses are far more likely to occur in otherwise healthy individuals, and they are a leading cause of accidental death in young people. The morbidity and mortality of this disease are disproportionally high in terms of economic cost and emotional burden on survivors and their families. Given the immense toll that this disease takes on the lives of patients, caregivers, and society, it is critical for healthcare providers to understand how to screen for potentially at-risk patients, quickly diagnose those who are overdosing, and effectively treat patients when they see them in the hospital or ambulatory setting.
Naloxone, the antidote to opioid drugs, is an extremely effective agent with minimal side-effects. However, this medication is not being used as effectively as necessary, and it is not as readily available as it should be to save lives. In addition, healthcare providers do not know enough about naloxone, and patients who are overdosing outside a hospital setting do not always have timely access to the medication.
The purpose of this educational activity is to explain how healthcare providers can use screening and diagnostic tools to effectively identify high-risk patients and patients who present with an overdose. It will also review the appropriate treatments for opioid overdose. Lastly, this activity will examine barriers to access and review how healthcare providers can educate at-risk patients and their families about opioid safety, overdose reversal and how to administer naloxone at home.
Method of Participation
This activity should take approximately one hour to complete. Participants should first read the objectives and other introductory CME/CE information and then proceed to the educational activity. To receive credit for this activity, participants must complete the post-test with a passing score of 80% and then complete the evaluation. Credit is provided through December 31, 2017. No credit will be given after this date. There is no fee to participate in this activity.
In the event you have questions about this activity or are unable to retrieve the certificate, please email email@example.com and a certificate will be emailed within 2 weeks.
- Computer, tablet, or smartphone with internet access
- HTML5 compatible browser or Adobe Flash Player
Dannemiller is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Dannemiller designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.00 AMA PRA Category 1 Credit(s)™ for completing this program.
Dannemiller is accredited by the the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 090419. This program is accredited for 1.00 contact hour(s) which includes 0.50 hours of pharmacology.
Dannemiller is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is a knowledge based activity. Dannemiller has assigned 1.00 contact hours (0.10 CEU) of continuing pharmacy education credit to this activity. ACPE program number 0522-0000-15-022-H01-P.
In order to receive credit, pharmacist learners must complete the activity and the evaluation form. An NABP number and date of birth must be provided to obtain credit. If you still need to create an NABP e-Profile and obtain an ID number, please visit nabp.net.
Notification of successful completion will be communicated to the CPE Monitor system, where all pharmacy learners credits are stored. Learner errors providing NABP numbers and/or DOB will result in unsuccessful reporting of credits to the CPE Monitor system.
Perry G. Fine, MD
Professor of Anesthesiology
Pain Research Center, School of Medicine
University of Utah
Salt Lake City, Utah
Jeffrey Gudin, MD
Director, Pain Management and Palliative Care
Englewood Hospital and Medical Center
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
The following faculty have disclosed the following:
- Dr. Brennan discloses he is a consultant and speaker for Milleniom and a consultant for Asta Zeneca.
- Dr. Fine discloses he is a consultant for Kaleo, Pfizer, Zogenix and Magellan Health.
- Dr. Gudin discloses he is a speaker for Salix, Purdue, Iroko, Teva and Astra Zeneca.
Dr. Bernard Abrams, content reviewer; Gloria Herrera, RN, MSN, FNP-BC, content reviewer and Gordon Ringler, Dannemiller Director or Medical Education have no financial relationships with commercial interests.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller or Kaleo. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.